Back to news

SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™

Globe Newswire•16/11/2026•08:30 ET
0

Key Highlights

  • ➤Q3 revenue $1.25 million, up approximately 265% sequentially
  • ➤REZENOPY initial wholesale shipments generated approximately $925,000 in Q3 revenue
  • ➤Q3 gross profit $1.02 million, up approximately 77.5% year-over-year
  • ➤First nine-month revenue $1.65 million, up approximately 176% year-over-year
  • ➤Management believes Scienture can achieve $6 million breakeven operating income and profitability in 2027

Expert Statements

Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture

“Our third-quarter results demonstrate the accelerating commercial momentum of Scienture as we begin generating meaningful revenue from two FDA-approved pharmaceutical products.”

Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture

“Revenue increased approximately 265% sequentially to $1.25 million and more than doubled year-over-year.”

Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture

“This growth reflects approximately $925,000 of net revenue from initial wholesale shipments of REZENOPY(™) following its August launch, alongside continued progress with Arbli(™).”

Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture

“We also generated more than $1.0 million in quarterly gross profit, reflecting what we see as attractive margins of our expanding commercial portfolio.”

Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture

“With much of the commercial infrastructure for both products already established, we are optimistic of revenue and margin expansion in the coming quarters.”

Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture

“We remain focused on expanding market access, strengthening distribution and accelerating product adoption to drive sustainable revenue growth and achieve our objective of profitability in 2027.”

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture

“Arbli(™) continues to gain commercial traction, while the successful launch of REZENOPY(™) has added a second revenue stream and established our presence in the opioid overdose treatment market.”

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture

“We are particularly encouraged by the progress of REZENOPY(™) beyond traditional wholesale distribution, including the fulfillment of our first orders through a dedicated direct customer channel that provides access to approximately 2,000 opioid treatment clinics and addiction treatment centers nationwide.”

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture

“Building on this momentum, we are actively pursuing additional distribution relationships, particularly within government markets, where we see opportunities to expand product access, diversify revenue streams and establish a scalable commercial platform to support long-term growth.”

Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million

Arbli(™) generated approximately $330,000 and $730,000 of Net Product Revenue for Q3 2026 and the first nine months of 2026 respectively

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in